845552-76-3

Usage

Uses

Used in Pharmaceutical Research:
Spiro[piperidine-4,3'-[3H]pyrrolo[2,3-b]pyridine], 1',2'-dihydro-1-(phenylMethyl)is employed as a crucial building block in pharmaceutical research for the development of new drug candidates. Its unique spirocyclic structure and the presence of a piperidine and pyrrolopyridine ring system contribute to its potential as a versatile scaffold for the design and synthesis of innovative therapeutic agents.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, Spiro[piperidine-4,3'-[3H]pyrrolo[2,3-b]pyridine], 1',2'-dihydro-1-(phenylMethyl)serves as a valuable starting material for the synthesis of diverse bioactive compounds. Its structural features allow for various chemical modifications, enabling the exploration of its potential as a precursor for the creation of new pharmaceutical agents with improved pharmacological properties.
Used in Drug Discovery:
The unique structural attributes of Spiro[piperidine-4,3'-[3H]pyrrolo[2,3-b]pyridine], 1',2'-dihydro-1-(phenylMethyl)make it an attractive candidate for drug discovery. Its potential biological activities, stemming from its distinct spirocyclic arrangement, warrant further investigation to uncover its therapeutic potential and explore its applicability in the treatment of various diseases and conditions.
Used in Drug Development:
As a promising chemical entity, Spiro[piperidine-4,3'-[3H]pyrrolo[2,3-b]pyridine], 1',2'-dihydro-1-(phenylMethyl)is utilized in drug development to create novel therapeutic agents with enhanced efficacy and selectivity. Its unique structural features provide a solid foundation for the optimization of drug candidates, leading to the development of more effective and safer medications for various medical needs.

Upstream product

• 42330-59-6 (2-chloropyrid-3-yl)methanol 
• 89581-84-0 2-chloro-3-(chloromethyl)pyridine 
• 101012-32-2 2-(2-chloropyridin-3-yl)acetonitrile 
• 845552-77-4 1-benzyl-4-(2-chloropyridin-3-yl)piperidine-4-carbonitrile 
• 55-51-6 N,N-bis(2-chloro-ethyl)-benzenemethanamine 
• 1021303-49-0 C₁₈H₂₂ClN₃ 

Downstream Products

• 845552-79-6 1-benzyl-1'-methyl-1',2'-dihydrospiro[piperidine-4,3'-pyrrol[2,3-b]pyridine] 
• 1606979-88-7 C₁₉H₂₃N₃O₂S 

Relevant academic research and scientific papers

Process Development for the Synthesis of a Selective M1 and M4 Muscarinic Acetylcholine Receptors Agonist

A practical and chromatography-free synthetic process to selective M1 and M4 muscarinic acetylcholine receptors agonist was developed and demonstrated on a several hundred gram scale. The key feature of this route is N,N-dimethylcarb

Experimental and computational study of intermolecular migration of N,N-dimethylcarbamoyl group from N(7) to N(1) on a 7-azaindoline derivative

N,N-Dimethylcarbamoylation of the anilinic nitrogen atom N(1) on the spiro 7-azaindoline consists of two steps. The first step is N,N- dimethylcarbamoylation of the pyridyl nitrogen atom N(7), leading to the formation of an isolable intermediate. The second step is intermolecular migration of the N,N-dimethylcarbamoyl group from the pyridyl nitrogen atom N(7) to the anilinic nitrogen atom N(1). We accomplished optimization of the reaction conditions based on the revealed reaction mechanism and a large scale synthesis of compound 3 in quantitative yield.

Discovery of N-substituted 7-azaindoline derivatives as potent, orally available M1 and M4 muscarinic acetylcholine receptors selective agonists

We designed and synthesized novel N-substituted 7-azaindoline derivatives as selective M1 and M4 muscarinic acetylcholine receptors (mAChRs) agonists. Hybridization of compound 2 with the HTS hit compound 5 followed by optimization of the N-substituents of 7-azaindoline led to identification of compound 1, which showed highly selective M1 and M4 mAChRs agonistic activity, weak human ether-a-go-go related gene inhibition, and good bioavailability in multiple animal species.

TETRAHYDROISOQUINOLINE OR ISOCHROMAN COMPOUNDS AS ORL-1 RECEPTOR LIGANDS FOR THE TREATMENT OF PAIN AND CNS DISORDERS

This invention provides the compounds of formula (I), or its a pharmaceutically acceptable ester or amide of such compound, or a pharmaceutically acceptable salt thereof, wherein X1 is NH; R1, R2, R4 through Rs